{"id":"nepafenac-nevanac","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Corneal erosion or ulceration"}]},"_chembl":{"chemblId":"CHEMBL1021","moleculeType":"Small molecule","molecularWeight":"254.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nepafenac is a prodrug that is converted to amfenac in ocular tissues. It works by inhibiting COX-1 and COX-2 enzymes, thereby reducing the synthesis of inflammatory prostaglandins. This mechanism reduces ocular inflammation, pain, and swelling associated with cataract surgery and other inflammatory eye conditions.","oneSentence":"Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin production and inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:58.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pain and inflammation associated with cataract surgery"},{"name":"Reduction of ocular inflammation following cataract surgery"}]},"trialDetails":[{"nctId":"NCT07162818","phase":"PHASE4","title":"Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2021-04-28","conditions":"Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment","enrollment":61},{"nctId":"NCT00801905","phase":"PHASE2","title":"Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2008-08","conditions":"Macular Thickening, Macular Edema","enrollment":50},{"nctId":"NCT05072262","phase":"PHASE4","title":"DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-11-25","conditions":"Descemet Stripping Automated Endothelial Keratoplasty (DSAEK), Descemet Membrane Endothelial Keratoplasty (DMEK)","enrollment":300},{"nctId":"NCT05331690","phase":"PHASE4","title":"Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN)","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2022-11-25","conditions":"Cataract Surgery","enrollment":500},{"nctId":"NCT03499873","phase":"PHASE3","title":"Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-03-28","conditions":"Cataract","enrollment":448},{"nctId":"NCT01939691","phase":"PHASE4","title":"Macular Edema Nepafenac vs. Difluprednate Uveitis Trial","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2018-09-12","conditions":"Uveitis, Macular Edema","enrollment":9},{"nctId":"NCT01310127","phase":"PHASE4","title":"Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2010-11","conditions":"Inflammation, Pseudophakia","enrollment":23},{"nctId":"NCT03918590","phase":"PHASE4","title":"Post Intravitreal Injection Topical NSAID vs. Patching","status":"UNKNOWN","sponsor":"The New York Eye & Ear Infirmary","startDate":"2018-12-03","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT03886779","phase":"PHASE4","title":"Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial","status":"COMPLETED","sponsor":"Silverstein Eye Centers","startDate":"2013-10-30","conditions":"Treatment of Ocular Inflammation Associated With Cataract Surgery","enrollment":57},{"nctId":"NCT01847638","phase":"NA","title":"Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery","status":"COMPLETED","sponsor":"Melissa Toyos","startDate":"2013-04-01","conditions":"Cataract, Retinal Edema, Inflammation","enrollment":50},{"nctId":"NCT01657266","phase":"PHASE2","title":"Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2013-12","conditions":"Cataract, Phacoemulsification Cataract Surgery","enrollment":160},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT02955641","phase":"NA","title":"Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2016-11-01","conditions":"Glaucoma, Closed-Angle, Glaucoma, Narrow-Angle, Glaucoma, Angle-Closure","enrollment":100},{"nctId":"NCT03406689","phase":"NA","title":"Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2017-09-01","conditions":"Pain","enrollment":99},{"nctId":"NCT00780780","phase":"PHASE3","title":"Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2007-07","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT02515045","phase":"PHASE4","title":"Dropless vs. Standard Drops Contralateral Eye Study","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2015-01","conditions":"Cataract","enrollment":59},{"nctId":"NCT02821390","phase":"NA","title":"Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2016-06","conditions":"Pain","enrollment":55},{"nctId":"NCT02752646","phase":"NA","title":"Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%","status":"COMPLETED","sponsor":"MDbackline, LLC","startDate":"2016-04","conditions":"Cataract","enrollment":200},{"nctId":"NCT00330798","phase":"PHASE4","title":"A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-02","conditions":"Photorefractive Keratectomy","enrollment":40},{"nctId":"NCT01475877","phase":"","title":"Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy","status":"COMPLETED","sponsor":"Virdi Eye Clinic","startDate":"2011-05","conditions":"Myopia","enrollment":20},{"nctId":"NCT02443012","phase":"PHASE4","title":"Topical Nepafenac as Supplement for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2013-03","conditions":"Diabetic Macular Edema","enrollment":47},{"nctId":"NCT00900887","phase":"PHASE2","title":"Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema","status":"COMPLETED","sponsor":"Hospital Juarez de Mexico","startDate":"2008-04","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":84},{"nctId":"NCT02084576","phase":"PHASE4","title":"Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification","status":"COMPLETED","sponsor":"Hospital Oftalmologico de Brasilia","startDate":"2013-08","conditions":"Cystoid Macular Edema, Cataract","enrollment":40},{"nctId":"NCT01995890","phase":"PHASE4","title":"Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes","status":"COMPLETED","sponsor":"Dr T V Patel Eye Institute","startDate":"2012-12","conditions":"Intraocular Pressure","enrollment":327},{"nctId":"NCT01318499","phase":"PHASE2","title":"Nepafenac 0.3% Two Study","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Cataract","enrollment":1342},{"nctId":"NCT01109173","phase":"PHASE3","title":"Confirmatory Study Nepafenac 0.3%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-06","conditions":"Cataract","enrollment":2120},{"nctId":"NCT00782717","phase":"PHASE2","title":"A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-11","conditions":"Macular Edema","enrollment":263},{"nctId":"NCT00939276","phase":"PHASE3","title":"Macular Edema Incidence/Severity Reduction With Nevanac","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2009-08","conditions":"Diabetic Retinopathy","enrollment":175},{"nctId":"NCT00332774","phase":"PHASE3","title":"Nevanac 3-Month Safety Study With QID Dosing","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-02","conditions":"Cataract","enrollment":149},{"nctId":"NCT01001806","phase":"PHASE4","title":"A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2009-10","conditions":"Cataracts","enrollment":126},{"nctId":"NCT01021761","phase":"PHASE4","title":"A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2009-10","conditions":"Cataracts","enrollment":126},{"nctId":"NCT00333255","phase":"PHASE3","title":"Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-09","conditions":"Cataract","enrollment":267},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00869219","phase":"PHASE4","title":"Comparison of Pain Sensation During Single Use of Two Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)","status":"UNKNOWN","sponsor":"Santa Casa de Misericordia de Santos","startDate":"2009-03","conditions":"Pain","enrollment":40},{"nctId":"NCT00377546","phase":"PHASE4","title":"Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Vitrectomy","enrollment":""},{"nctId":"NCT00348582","phase":"PHASE4","title":"Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Cataract","enrollment":""},{"nctId":"NCT00347204","phase":"PHASE4","title":"Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK","status":"COMPLETED","sponsor":"Center For Excellence In Eye Care","startDate":"2006-01","conditions":"Myopia, Hyperopia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nepafenac (Nevanac)","genericName":"Nepafenac (Nevanac)","companyName":"Center For Excellence In Eye Care","companyId":"center-for-excellence-in-eye-care","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nepafenac, also known as Nevanac, is a small molecule cyclooxygenase inhibitor used to treat various eye conditions. It is indicated for conditions such as cataract, macular edema, myopia, hyperopia, and cystoid macular edema, among others.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}